Literature DB >> 30912021

3D-3 Tumor Models in Drug Discovery for Analysis of Immune Cell Infiltration.

Annika Osswald1, Viola Hedrich1, Wolfgang Sommergruber2.   

Abstract

The cross talk between tumor cells and other cells present in the tumor microenvironment such as stromal and immune cells highly influences the behavior and progression of disease. Understanding the underlying mechanisms of interaction is a prerequisite to develop new treatment strategies and to prevent or at least reduce therapy failure in the future. Specific reactivation of the patient's immune system is one of the major goals today. However, standard two-dimensional (2D) cell culture techniques lack the necessary complexity to address related questions. Novel three-dimensional (3D) in vitro models-embedded in a matrix or encapsulated in alginate-recapitulate the in vivo situation much better. Cross talk between different cell types can be studied starting from co-cultures. As cancer immune modulation is becoming a major research topic, 3D in vitro models represent an important tool to address immune regulatory/modulatory questions for T, NK, and other cells of the immune system. The 3D systems consisting of tumor cells, fibroblasts, and immune cells (3D-3) already proved as a reliable tool for us. For instance, we made use of those models to study the molecular mechanisms of the cross talk of non-small cell lung cancer (NSCLC) and fibroblasts, to unveil macrophage plasticity in the tumor microenvironment and to mirror drug responses in vivo. Generation of those 3D models and how to use them to study immune cell infiltration and activation will be described in the present book chapter.

Entities:  

Keywords:  3D culture; Alginate capsules; Bioreactor; Floater; Immune cell infiltration; Matrigel/collagen; NK cell; Non-small cell lung cancer (NSCLC); Spheroid; T cell

Mesh:

Substances:

Year:  2019        PMID: 30912021     DOI: 10.1007/978-1-4939-9145-7_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Detection of lncRNA by LNA-Based In Situ Hybridization in Paraffin-Embedded Cancer Cell Spheroids.

Authors:  Boye Schnack Nielsen; Jesper Larsen; Jakob Høffding; Son Ly Nhat; Natasha Helleberg Madsen; Trine Møller; Bjørn Holst; Kim Holmstrøm
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Cell Culture Based in vitro Test Systems for Anticancer Drug Screening.

Authors:  Kristina V Kitaeva; Catrin S Rutland; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Front Bioeng Biotechnol       Date:  2020-04-09

Review 3.  3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs.

Authors:  Mélanie A G Barbosa; Cristina P R Xavier; Rúben F Pereira; Vilma Petrikaitė; M Helena Vasconcelos
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

4.  Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Neel I Nissen; Astrid Z Johansen; Inna Chen; Julia S Johansen; Rasmus S Pedersen; Carsten P Hansen; Morten A Karsdal; Nicholas Willumsen
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

5.  Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.

Authors:  Jesse J Lipp; Limei Wang; Haitang Yang; Feng Yao; Nathalie Harrer; Stefan Müller; Sabina Berezowska; Patrick Dorn; Thomas M Marti; Ralph A Schmid; Belazs Hegedüs; Abdallah Souabni; Sebastian Carotta; Mark A Pearson; Wolfgang Sommergruber; Greg J Kocher; Sean R R Hall
Journal:  Oncoimmunology       Date:  2022-02-09       Impact factor: 8.110

6.  Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.

Authors:  David J Lamb; Aleksander Rust; Albin Rudisch; Tobias Glüxam; Nathalie Harrer; Herwig Machat; Ingrid Christ; Florian Colbatzky; Andreas Wernitznig; Annika Osswald; Wolfgang Sommergruber
Journal:  Oncotarget       Date:  2020-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.